Inventiva SA
IVA5.880USD
+0.080+1.38%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Inventiva SA Company
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Inventiva SA Info
Ticker SymbolIVA
Company nameInventiva SA
IPO dateFeb 15, 2017
CEOObenshain (Andrew)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address50 rue de Dijon
CityDAIX
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code21121
Phone33380447500
Websitehttps://inventivapharma.com/
Ticker SymbolIVA
IPO dateFeb 15, 2017
CEOObenshain (Andrew)
Company Executives of Inventiva SA
Name
Name/Position
Position
Shareholding
Change
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Eric Duranson
Mr. Eric Duranson
General Counsel
General Counsel
--
--
Ms. Pascaline Clerc
Ms. Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Executive Vice President - Strategy and Corporate Affairs
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Ms. Alice Roudot-Ketelers
Ms. Alice Roudot-Ketelers
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Feb 2
Updated: Mon, Feb 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
3.73%
Deep Track Capital LP
2.27%
Yiheng Capital Management, L.P.
1.90%
UBS Financial Services, Inc.
1.90%
Polar Capital LLP
1.36%
Other
88.83%
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
3.73%
Deep Track Capital LP
2.27%
Yiheng Capital Management, L.P.
1.90%
UBS Financial Services, Inc.
1.90%
Polar Capital LLP
1.36%
Other
88.83%
Shareholder Types
Shareholders
Proportion
Venture Capital
5.03%
Investment Advisor
3.90%
Hedge Fund
2.85%
Investment Advisor/Hedge Fund
1.38%
Research Firm
0.02%
Other
86.82%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
29
15.17M
10.90%
+10.19M
2025Q3
21
4.95M
5.18%
+27.37K
2025Q2
19
4.87M
5.09%
-661.07K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Samsara BioCapital, LLC
5.19M
3.73%
+5.19M
--
Nov 17, 2025
Yiheng Capital Management, L.P.
2.64M
1.9%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
9.12K
0.01%
-18.33K
-66.77%
Sep 30, 2025
New Enterprise Associates (NEA)
1.46M
1.05%
--
--
Sep 30, 2025
BVF Partners L.P.
686.04K
0.49%
--
--
Nov 17, 2025
Millennium Management LLC
112.03K
0.08%
+112.03K
--
Sep 30, 2025
Commonwealth Financial Network
64.86K
0.05%
+10.54K
+19.40%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
